Baricitinib for the treatment of rheumatoid arthritis

Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study

(2016) Y. Tanaka et al.   JOURNAL OF RHEUMATOLOGY

RA-BEACON illuminates baricitinib

(2016) Dario Ummarino   Nature Reviews Rheumatology

Baricitinib in Patients with Refractory Rheumatoid Arthritis

(2016) Mark C. Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

(2015) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro

(2014) Sheau-Pey Wang et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

(2014) Edward C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers

(2014) Jack G. Shi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta-Analysis

(2014) Alejandro Souto et al.   Arthritis & Rheumatology

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis

(2014) Kevin L. Winthrop et al.   Arthritis & Rheumatology

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

(2013) Joel Kremer et al.   ANNALS OF INTERNAL MEDICINE

The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells

(2013) Satoshi Kubo et al.   ANNALS OF THE RHEUMATIC DISEASES

Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study

(2013) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study

(2012) Sarah Parish et al.   CIRCULATION

JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

(2012) John J. O'Shea et al.   IMMUNITY

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells

(2011) Keisuke Maeshima et al.   ARTHRITIS AND RHEUMATISM

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) D. Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

(2010) J. S. Fridman et al.   JOURNAL OF IMMUNOLOGY

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women

(2009) Samia Mora et al.   CIRCULATION

Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis

(2009) Shin-ya Kawashiri et al.   RHEUMATOLOGY INTERNATIONAL

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY